Mebeverine Hydrochloride Aspire Pharma

Mebeverine Hydrochloride, the active ingredient in Mebeverine Hydrochloride Aspire Pharma, is an antispasmodic (smooth muscle relaxant) presented as an oral dosage form for oral use. It treats irritable bowel syndrome and related functional bowel disorders in adults.

GNH USA supplies Mebeverine Hydrochloride Aspire Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mebeverine Hydrochloride is a gastrointestinal antispasmodic used to manage conditions characterized by smooth‑muscle spasm.

Irritable bowel syndrome (IBS): reduces abdominal pain, cramping and altered bowel habits associated with IBS. Functional bowel disorders: alleviates discomfort and irregular motility in functional gastrointestinal conditions. Gastrointestinal smooth‑muscle spasm: relaxes spastic segments of the gut, improving passage of contents and decreasing pain.

Mebeverine Hydrochloride may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth - Nausea or mild stomach upset - Headache - Dizziness - Fatigue - Mild skin rash

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Persistent tachycardia or palpitations - Significant hypotension - Hepatic dysfunction (elevated liver enzymes) - Acute urinary retention - Severe skin reactions such as Stevens‑Johnson syndrome

Before initiating therapy, consider the following safety measures.

Pregnancy: safety not established; use only if clearly needed. Breastfeeding: unknown excretion; weigh benefits against potential risks. Renal or hepatic impairment: monitor clinical response and adjust if necessary. Drug interactions: review concomitant medications for potential interactions. Elderly patients: start at lower dose and monitor for adverse effects. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Mebeverine Hydrochloride can interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – may increase plasma levels. - Anticholinergic agents – additive reduction of gut motility.

Moderate Interactions (Monitor Closely): - Other antispasmodics – risk of excessive smooth‑muscle relaxation. - Antihypertensives – possible additive hypotensive effect. - Drugs affecting electrolyte balance – monitor for arrhythmias.